GlassScriptPhysician profile
Ryan Mckay Rich
NPI 1992720064
$6,647.80
in general payments reported to CMS, 2019-2025
13 companies · $29.68 in 2025
The $29.68 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $604 · 2021: $1,072 · 2022: $1,056 · 2023: $3,368 · 2024: $17.78 · 2025: $29.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $3,326 · Food and Beverage: $89.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $3,325.80 |
| Food and Beverage | $89.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $5,970.13 | 2019-2023 | |
| Alcon Vision LLC | $230.57 | 2020-2021 | |
| Genentech USA, INC. | $135.72 | 2020-2023 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $124.75 | 2022 | |
| Novartis Pharmaceuticals Corporation | $71.58 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $29.68 | 2025 | Syfovre |
| Eyepoint US, INC. | $23.58 | 2021 | |
| Genentech, INC. | $23.19 | 2019 | |
| Abbvie INC. | $17.78 | 2024 | |
| Allergan, INC. | $14.25 | 2019 | |
| Optos, INC. | $6.57 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$31,697.61 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.